Literature DB >> 23624097

Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.

Gary R Matyas1, Alexander V Mayorov, Kenner C Rice, Arthur E Jacobson, Kejun Cheng, Malliga R Iyer, Fuying Li, Zoltan Beck, Kim D Janda, Carl R Alving.   

Abstract

In order to create an effective immunization approach for a potential vaccine to heroin, liposomes containing monophosphoryl lipid A [L(MPLA)] were tested as an adjuvant system to induce antibodies to heroin hapten analogs. Four synthetic haptens and two immunization strategies were employed. In the first strategy, a hydrophobic 23 amino acid immunogenic peptide derived from the membrane proximal external region of gp41 from HIV-1 envelope protein was embedded as a carrier in the outer surface of L(MPLA), to which was conjugated a 15 amino acid universal T cell epitope and a terminal heroin hapten analog. In the second strategy, tetanus toxoid (TT) carrier protein was decorated with haptens by conjugation, and the hapten-conjugated protein was mixed with L(MPLA). After immunization of mice, each of the immunization strategies was effective for induction of IgG anti-hapten antibodies. The first immunization strategy induced a mean end-point IgG titer against one of two haptens tested of approximately 12,800; however, no detectable antibodies were induced against the liposome-associated HIV-1 carrier peptide. In the second immunization strategy, depending on the hapten used for decorating the TT, end-point IgG titers ranged from 100,000 to 6,500,000. In this strategy, in which hapten was conjugated to the TT, end-point IgG titers of 400,000 to the TT carrier were observed with each conjugate. However, upon mixing unconjugated TT with L(MPLA), anti-TT titers of 6,500,000 were observed. We conclude that L(MPLA) serves as a potent adjuvant for inducing antibodies to candidate heroin haptens. However, antibodies to the carrier peptide or protein were partly or completed inhibited by the presence of conjugated hapten. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23624097      PMCID: PMC4120113          DOI: 10.1016/j.vaccine.2013.04.027

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

1.  2.3 A crystal structure of tetanus neurotoxin light chain.

Authors:  Mark A Breidenbach; Axel T Brunger
Journal:  Biochemistry       Date:  2005-05-24       Impact factor: 3.162

2.  Effects of a nicotine conjugate vaccine on the acquisition and maintenance of nicotine self-administration in rats.

Authors:  Mark G LeSage; Daniel E Keyler; Yoko Hieda; Greg Collins; Danielle Burroughs; Chap Le; Paul R Pentel
Journal:  Psychopharmacology (Berl)       Date:  2005-07-01       Impact factor: 4.530

3.  Imject Alum is not aluminum hydroxide adjuvant or aluminum phosphate adjuvant.

Authors:  Stanley L Hem; Cliff T Johnston; Harm HogenEsch
Journal:  Vaccine       Date:  2007-05-15       Impact factor: 3.641

Review 4.  Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors.

Authors:  Benito Anton; Alberto Salazar; Anabel Flores; Maura Matus; Rodrigo Marin; Jorge-Alberto Hernandez; Philippe Leff
Journal:  Hum Vaccin       Date:  2009-04-08

Review 5.  Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides.

Authors:  C R Alving; V Koulchin; G M Glenn; M Rao
Journal:  Immunol Rev       Date:  1995-06       Impact factor: 12.988

Review 6.  Immunotherapy for the treatment of drug abuse.

Authors:  Thomas Kosten; S Michael Owens
Journal:  Pharmacol Ther       Date:  2005-10       Impact factor: 12.310

7.  Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes.

Authors:  Gary R Matyas; Lindsay Wieczorek; Zoltan Beck; Christina Ochsenbauer-Jambor; John C Kappes; Nelson L Michael; Victoria R Polonis; Carl R Alving
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

8.  A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents.

Authors:  Benito Anton; Philippe Leff
Journal:  Vaccine       Date:  2006-02-08       Impact factor: 3.641

Review 9.  Anti-drug vaccines to treat substance abuse.

Authors:  Berma M Kinsey; David C Jackson; Frank M Orson
Journal:  Immunol Cell Biol       Date:  2009-03-31       Impact factor: 5.126

10.  Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41.

Authors:  Douglas S Watson; Francis C Szoka
Journal:  Vaccine       Date:  2009-06-09       Impact factor: 3.641

View more
  36 in total

1.  A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats.

Authors:  Michael D Raleigh; Federico Baruffaldi; Samantha J Peterson; Morgan Le Naour; Theresa M Harmon; Jennifer R Vigliaturo; Paul R Pentel; Marco Pravetoni
Journal:  J Pharmacol Exp Ther       Date:  2018-11-08       Impact factor: 4.030

Review 2.  Development of vaccines to treat opioid use disorders and reduce incidence of overdose.

Authors:  Marco Pravetoni; Sandra D Comer
Journal:  Neuropharmacology       Date:  2019-06-04       Impact factor: 5.250

3.  Heroin vaccine: Using titer, affinity, and antinociception as metrics when examining sex and strain differences.

Authors:  Candy S Hwang; Lauren C Smith; Cody J Wenthur; Beverly Ellis; Bin Zhou; Kim D Janda
Journal:  Vaccine       Date:  2019-06-05       Impact factor: 3.641

Review 4.  Conjugate Vaccine Immunotherapy for Substance Use Disorder.

Authors:  Paul T Bremer; Kim D Janda
Journal:  Pharmacol Rev       Date:  2017-07       Impact factor: 25.468

5.  Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriers.

Authors:  Rashmi Jalah; Oscar B Torres; Alexander V Mayorov; Fuying Li; Joshua F G Antoline; Arthur E Jacobson; Kenner C Rice; Jeffrey R Deschamps; Zoltan Beck; Carl R Alving; Gary R Matyas
Journal:  Bioconjug Chem       Date:  2015-06-05       Impact factor: 4.774

Review 6.  Adjuvants for vaccines to drugs of abuse and addiction.

Authors:  Carl R Alving; Gary R Matyas; Oscar Torres; Rashmi Jalah; Zoltan Beck
Journal:  Vaccine       Date:  2014-08-08       Impact factor: 3.641

Review 7.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

Review 8.  Biologic Approaches to Treat Substance-Use Disorders.

Authors:  Phil Skolnick
Journal:  Trends Pharmacol Sci       Date:  2015-10       Impact factor: 14.819

9.  Scientific overview: 2013 BBC plenary symposium on tobacco addiction.

Authors:  M De Biasi; I McLaughlin; E E Perez; P A Crooks; L P Dwoskin; M T Bardo; P R Pentel; D Hatsukami
Journal:  Drug Alcohol Depend       Date:  2014-06-02       Impact factor: 4.492

10.  Synthesis and immunological effects of heroin vaccines.

Authors:  Fuying Li; Kejun Cheng; Joshua F G Antoline; Malliga R Iyer; Gary R Matyas; Oscar B Torres; Rashmi Jalah; Zoltan Beck; Carl R Alving; Damon A Parrish; Jeffrey R Deschamps; Arthur E Jacobson; Kenner C Rice
Journal:  Org Biomol Chem       Date:  2014-10-07       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.